2012年3月6日 · ARCUS is a novel and proprietary genome editing platform discovered and developed by scientists at Precision BioSciences. ARCUS uses sequence- specific DNA …

©2021 Precision BioSciences "This website uses cookies for functionality, analytics, personalized content, and ads. By clicking the “Accept All Cookies” or "Accept Non-Essential Cookies" …

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency. …

The high specificity and single component nature of Precision’s mitoARCUS nucleases are designed to enable specific editing of mutant mitochondrial DNA while allowing the normal …

Precision ARCUS nucleases have a number of inherent traits that make them promising tools for targeted, precise, and safe gene-editing therapeutic applications. Most importantly, they have …

But rapid advances and breakthroughs mean that moving from cell culture to the clinic is now an exciting reality – and Precision has quietly built what is arguably the leading gene editing …

2024年9月3日 · Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that …

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

2024年10月29日 · Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that …

Precision BioSciences is a company and a community dedicated to improving life. This isn’t just a statement supporting the products that we’re developing – it is our collective desire to do our …